



PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/617,489	
	Filing Date	July 10, 2003	
	First Named Inventor	Thomas L. CANTOR	
	Art Unit	1641	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	7	Attorney Docket Number	532212000623

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement, 3 PAGES <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> _____ <input type="checkbox"/> _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449, 3 pages; Return Postcard.
Remarks CUSTOMER NO. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP Peng Chen - 43,543
Signature	
Date	February 25, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: 2-25-2004 Signature: Rhea Amid (Rhea Amid)



PATENT
Docket No. 532212000623

CERTIFICATE OF MAILING BY "FIRST CLASS"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on February 25, 2004.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas L. CANTOR

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES
FOR DETECTING PARATHYROID
HORMONE

Examiner: Not Yet Assigned

Group Art Unit: 1641

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action directed to the following related applications: Serial No. 09/231,422 filed 14 January 1999 and issued 10 February 2004 as U.S. Patent No. 6,689,566, and Serial No. 09/344,639 filed 26 June 1999, now allowed. Accordingly, copies are not included herewith. This protocol

conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

Applicant respectfully submits that Ref. No. 5 (Pub. No. 2002/0160945 A1) was previously identified as U.S. App. No. 09/928,047; Ref. No. 6 (Pub. No. 2003/0138858 A1) was previously identified as U.S. App. No. 09/928,048; and Ref. No. 12 (U.S. Patent No. 6,524,788) was previously identified as U.S. App. No. 10/002,818.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000623. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 25, 2004

Respectfully submitted,

By: 
Peng Chen
Reg. No. 43,543
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 532212000623

Application Number 10/617,489

Applicant

Thomas L. CANTOR

Filing Date July 10, 2003

Group Art Unit 1641

Mailing Date: February 25, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.		60/224,396	Cantor			08/10/00
	2.		09/323,606	Cantor			06/02/99
	3.		09/636,530	Cantor			08/10/01
	4.		09/636,531	Cantor			08/10/00
	5.	10/2002	2002/0160945 A1	Cantor	514	012	
	6.	07/2003	2003/0138858 A1	Cantor	435	007.9	
	7.	01/1983	4,369,138	Lindall	260	112.5	
	8.	12/1983	4,423,037	Rosenblatt et al.	424	177	
	9.	04/1985	4,508,828	Lindall et al.	436	500	
	10.	04/1987	4,656,250	Morita et al.	530	324	
	11.	02/2000	6,030,790	Adermann et al.	435	7.1	
	12.	02/2003	6,524,788	Cantor	435	004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	13.	07/1985	DE 33 47 548	Germany				X
	14.	04/1996	DE 44 34 551	Germany			X	
	15.	12/2001	EP 0 783 522	Europe			X	
	16.	05/1991	WO 91/06564	WIPO				
	17.	04/1993	WO 93/06845	WIPO				
	18.	02/1994	WO 94/03201	WIPO				
	19.	04/1996	WO 96/10041	WIPO			X	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 532212000623

Application Number 10/617,489

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Thomas L. CANTOR

Filing Date July 10, 2003

Group Art Unit 1641

Mailing Date: February 25, 2004

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	20.	Adermann et al., in: Innovations and Perspectives in Solid Phase Synthesis, Epton (ed.), Mayflower World Wide, Birmingham (1994) pp.429-432.
	21.	Atkinson et al., Journal of Immunoassay (1982) 3(1):31-51.
	22.	Blind et al., Clin. Chem. (1987) 33(8):1376-1381.
	23.	Bouillon, R. et al. (1990) Clin Chem 36(2):271-276.
	24.	Bowie et al., Science (1990) 247:1306-1310.
	25.	Brossard et al., Journal of Clinical Endocrinology and Metabolism (1996) 81(11):3923-3929.
	26.	Campbell, Monoclonal Antibody and Immunosensor Technology, in Laboratory Techniques in Biochemistry and Molecular Biology, van der Vliet (ed.), Elsevier (1991) pp.1-11, 42-45.
	27.	Caporale and Rosenblatt, Parathyroid Hormone Antagonists Effective in vivo, in: Advances in Experimental Medicine and Biology, New York (1986) pp. 315-327.
	28.	Cardinal, H. et al. (1998) J of Clinical Endocrinology & Metabolism 83(11):3839-3844.
	29.	Clinical Chemistry (1999) 45(6) Suppl:A97 b, Abstract Nos. 339-341.
	30.	Cohen Solal, M.-E., et al. (1991) J of Clinical Endocrinology & Metabolism 73(3):516-524.
	31.	D'Amour et al., Am. J. Physiol. (1986) 251:E680-E687.
	32.	D'Amour, P. et al. (1992) J of Clinical Endocrinology & Metabolism 74(3):525-532.
	33.	Daniel et al., Virology (1994) 202:540-549.
	34.	Fischer et al., The Journal of Clinical Investigation (1974) 54:1382-1394.
	35.	Fournier, A. et al. (2001) J of Clinical Endocrinology & Metabolism 86(4):1840-1841.
	36.	Fournier, A. et al. (2002) Kidney Int 61(3):1181.
	37.	Gao et al., Clinica Chimica Acta (1996) 245:39-59.
	38.	Goodman, W.G., et al. (2001) J of Clinical Endocrinology & Metabolism 86(4):1841-1842.
	39.	Gordon et al., Parathyroid Hormone Domain for Protein Kinase C Stimulation Located within Amphiphilic Helix, in: Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium, June 16-21, 1991, Cambridge, MA, Smith and Rivier (eds.) Escrom Science Publishers (1992) pp.37-39.
	40.	Hashimoto et al., Journal of Cardiovascular Pharmacology (1981) 3(4):668-676.
	41.	Hehrmann et al., Journal of Immunoassay (1980) 1(2):151-174.
	42.	John et al., Journal of Clinical Endocrinology and Metabolism (1999) 84(11):4287-4290.
	43.	LePage et al., Clin. Chem. (1998) 44:805-810.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Application Number 10/617,489

Applicant


Thomas L. CANTOR

(Use several sheets if necessary)

Filing Date July 10, 2003

Group Art Unit 1641

Mailing Date: February 25, 2004

[illegible]

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.